Associated Genetic Biomarkers
BRAF N486_A489delinsK is present in 0.00% of AACR GENIE cases, with prostate cancer having the greatest prevalence .
BRAF N486_A489delinsK serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains BRAF N486_A489delinsK as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Trials with BRAF N486_A489delinsK in the inclusion eligibility criteria most commonly target malignant solid tumor .
Binimetinib and encorafenib are the most frequent therapies in trials with BRAF N486_A489delinsK as an inclusion criteria .
Significance of BRAF N486_A489delinsK in Diseases
Malignant Solid Tumor +
BRAF is mutated in 39.82% of malignant solid tumor patients .
BRAF N486_A489delinsK is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF N486_A489delinsK and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Binimetinib and encorafenib are the most frequent therapies in trials for malignant solid tumor that contain BRAF N486_A489delinsK .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.